Akkermansia and “GLP-1 Probiotics”: Small Trials, Modest Results and Mostly Company-Run Data
Probiotics containing Akkermansia muciniphila are marketed as a natural way to boost GLP-1. The GLP-1 link comes mainly from mouse research, the human trials are small, most were run by companies that sell the bacteria, and the results are far smaller than those of GLP-1 drugs.
By Kymata Health Editorial Published Last checked
Key takeaways
From 9 sources- The GLP-1 claim traces mainly to a 2021 mouse study in which an Akkermansia protein called P9 triggered GLP-1 release1.
- In the first human trial, 32 adults with overweight and insulin resistance finished 3 months on live or pasteurized Akkermansia or placebo; the pasteurized form improved insulin sensitivity 28.6% versus placebo, but its weight change was not statistically significant2.
- In the largest trial, 142 adults with metabolic syndrome, the primary insulin-sensitivity measure did not differ from placebo after 4 months3.
- After a diet, people taking pasteurized Akkermansia regained 1.2 kg versus 3.2 kg on placebo over 24 weeks4; for scale, semaglutide produced a 14.9% weight loss in its main trial7.
- Four of the five human trials covered here were run by companies that make Akkermansia products or by researchers who hold patents on it2346.
What this article covers
1 evidence profileThe evidence, graded
Pulled from the trial tables in our evidence profiles. Grades follow our evidence-grading policy.
Graded findings
5 rows- DGrade DInsulin sensitivity, insulin and cholesterol in overweight insulin resistanceImproved Pasteurized cells improved insulin sensitivity (+28.6%) and lowered insulin (−34%) and total cholesterol (−8.7%) versus placebo; weight fell 2.3 kg (P = 0.09). Both forms were safe and well tolerated.Akkermansia muciniphila · Pilot RCT · n=32 · 2019 · PMID 31263284
- CGrade CWhole-body insulin sensitivity in metabolic syndromeMixed The primary endpoint (Matsuda index) did not differ from placebo. Exploratory analyses found improvements in prediabetic, older and low-baseline-Akkermansia subgroups, including GLP-1 response.Akkermansia muciniphila · RCT · n=142 · 2026 · PMID 42343233
- CGrade CWeight regain after a low-energy dietImproved Weight regain was 1.2 kg versus 3.2 kg on placebo (P = 0.012), and net loss from baseline was 3.1 kg greater. No serious treatment-related adverse events.Akkermansia muciniphila · RCT · n=90 · 2026 · PMID 42120725
- DGrade DWeight and HbA1c in type 2 diabetes with overweightNo effect Weight and HbA1c fell in both groups with no between-group difference; in people with low baseline Akkermansia, the strain colonized well and lowered weight, fat mass and HbA1c.Akkermansia muciniphila · RCT · n=58 · 2025 · PMID 39879980
- DGrade DPost-meal glucose in type 2 diabetes (multi-strain product with Akkermansia)Improved Glucose area under the curve fell by 36.1 mg/dL/180 min versus placebo (P = 0.05), and HbA1c by 0.6 points; no safety or tolerability issues.Akkermansia muciniphila · RCT · n=76 · 2020 · PMID 32675291
Where these trials agree: Akkermansia muciniphila and weight, counted row by row in the Consensus finder.
Where the GLP-1 claim comes from
GLP-1 is the gut hormone that drugs such as semaglutide are built to mimic. Akkermansia muciniphila is a gut bacterium, and studies have linked lower levels of it with overweight, obesity, untreated type 2 diabetes and high blood pressure2.
In 2021, researchers reported that Akkermansia secretes a protein, P9, that triggered GLP-1 release and improved blood sugar control in mice fed a high-fat diet1. That is where the “GLP-1 probiotic” label comes from. It is a mouse result, and a bacterium that nudges the body’s own GLP-1 release is a different thing from a drug that acts on GLP-1 receptors.
What the human trials found
The human evidence comes from a few small randomized trials:
- Belgium, 2019: 40 adults with overweight or obesity and insulin resistance enrolled, and 32 finished 3 months of live or pasteurized Akkermansia or placebo2. Pasteurized cells improved insulin sensitivity by 28.6% and lowered insulin by 34% and total cholesterol by 8.7%; the 2.3 kg weight drop did not reach statistical significance2.
- Ireland and Germany, 2026: 142 adults with metabolic syndrome took 30 billion pasteurized cells a day or placebo for 4 months, and the primary insulin-sensitivity measure did not differ3. Exploratory analyses found larger GLP-1 rises after a glucose drink in some subgroups, chiefly people who started with low Akkermansia levels3.
- Netherlands, 2026: 90 adults started an 8-week low-energy diet aimed at losing at least 8% of body weight, then took pasteurized Akkermansia or placebo for 24 weeks4. Weight regain was 1.2 kg versus 3.2 kg, and no serious treatment-related adverse events occurred4.
- China, 2025: in 58 adults with type 2 diabetes and overweight, a live Akkermansia strain did not beat placebo on weight or HbA1c overall; people who started with low Akkermansia levels did better5.
- United States, 2020: in a 76-person, three-arm trial in type 2 diabetes, a five-strain product containing inulin and Akkermansia lowered the post-meal glucose curve by 36.1 mg/dL over 180 minutes versus placebo (P = 0.05) and HbA1c by 0.6 points6.
Who ran the studies
Industry ties run through this evidence. In the 2019 trial, five authors held patent applications on Akkermansia and two co-founded a company developing it2. In the 2026 metabolic syndrome trial, authors included employees, consultants and co-founders of The Akkermansia Company3, and the 2026 weight-maintenance trial’s authors included that company’s co-founder and chief technology officer, its chief medical officer and an employee4. All authors of the 2020 multi-strain trial were employees and stock or stock-option holders of Pendulum Therapeutics, the company behind the product6.
The 2025 Chinese trial, whose authors declared no competing interests, found no overall benefit over placebo5. Industry ties do not make a result wrong, but we found no large independent trial that confirms the positive results.
How this compares with GLP-1 drugs
For scale, in the main trial of semaglutide 2.4 mg a week, 1,961 adults with overweight or obesity lost 14.9% of body weight over 68 weeks, versus 2.4% on placebo7. None of the Akkermansia trials above reported weight loss on that scale, we found none that compared the two directly, and none tested Akkermansia as a substitute for a prescribed GLP-1 medicine.
If you take a GLP-1 medicine, our GLP-1 companion hub covers protein, strength training and what happens when you stop, and the metabolic health hub covers blood sugar options with stronger evidence. For comparison with another supplement sold as a natural Ozempic, see berberine’s evidence.
Safety and who should be cautious
In the trials above, Akkermansia was well tolerated, and no serious treatment-related adverse events were reported24. The European Food Safety Authority judged pasteurized Akkermansia safe for adults at up to 3.4 × 10^10 cells a day, provided live cells stay below the detection limit8. Points to weigh before trying it:
- Pregnancy and breastfeeding: EFSA concluded in 2025 that safety in pregnant and breastfeeding women has not been established9.
- Teenagers: EFSA set lower limits for adolescents, 2.1 × 10^10 cells a day at ages 12 to 13 and 3.0 × 10^10 at ages 14 to 179.
- Live versus pasteurized: the EU safety opinion covers pasteurized cells with live bacteria below the detection limit, not live-cell products8.
- Diabetes medicines: in the 2020 trial, HbA1c fell by 0.6 points6, so anyone on glucose-lowering drugs needs their prescriber to know before adding a product aimed at blood sugar.
- Labels and strains: the trials tested specific strains and doses, which a retail capsule may not match. Our guide to probiotic labels, CFUs and strains and the Akkermansia page explain what to check.
Quick answers
Common questions
4 answersIs Akkermansia a natural Ozempic?
Does Akkermansia help you lose weight?
Live or pasteurized Akkermansia?
Who should not take Akkermansia?
Its safety in pregnancy and breastfeeding has not been established9.
Keep reading
Full evidence profiles
Every graded study, studied doses, interactions and safetyRelated articles
4 articles- ArticleAlpha-GPC vs Choline Bitartrate: Blood Choline Rose the Same, but One Detail DifferedIs alpha-GPC better than choline bitartrate?
- ArticleAlpha-Lipoic Acid for Diabetic Neuropathy: Less Burning and Tingling, No Proven Nerve RepairDoes alpha-lipoic acid help diabetic neuropathy?
- ArticleApple Cider Vinegar Before Meals: What It Does to a Blood Sugar Spike, and What It Doesn'tDoes apple cider vinegar lower blood sugar after meals?
- ArticleApple Cider Vinegar for Weight Loss: The Viral 2024 Trial Was Retracted. Here Is What Is LeftDoes apple cider vinegar help you lose weight?
More on Supplements and vitamins
6 pages- TopicSupplements and vitamins: every page
- Previous400 IU of Vitamin E Is Either 268 mg or 180 mg. The "d" or "dl" on the Label DecidesVitamin E labels switched from IU to mg, and the conversion depends on whether the vitamin is natural or synthetic.
- In this topicApigenin for Sleep: No Trial Has Tested It on Its Own, and the Closest Evidence Is MixedApigenin, a flavone found in chamomile, has become a popular bedtime supplement.
- ToolEvidence-graded supplement stacks
- Also inGLP-1 weight loss
- TopicsBrowse all topics
Browse the full Supplement & Nutrient Encyclopedia or all supplement articles.
References
9 sources. Numbers in the text link here.
Sources cited in this article
9 sources- 1Akkermansia muciniphila secretes a glucagon-like peptide-1-inducing protein that improves glucose homeostasis and ameliorates metabolic disease in miceNat Microbiol, 2021 · PMID 33820962
- 2Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory studyNat Med, 2019 · PMID 31263284
- 3Effect of pasteurized Akkermansia muciniphila MucT on insulin sensitivity, body composition, and GLP-1 production in subjects with metabolic syndrome: impact of low baseline gut Akkermansia levelsGut Microbes, 2026 · PMID 42343233
- 4Pasteurized Akkermansia muciniphila Muc(T) for weight loss maintenance in people with overweight and obesity: a controlled randomized trialNat Med, 2026 · PMID 42120725
- 5Akkermansia muciniphila supplementation in patients with overweight/obese type 2 diabetes: Efficacy depends on its baseline levels in the gutCell Metab, 2025 · PMID 39879980
- 6Improvements to postprandial glucose control in subjects with type 2 diabetes: a multicenter, double blind, randomized placebo-controlled trial of a novel probiotic formulationBMJ Open Diabetes Res Care, 2020 · PMID 32675291
- 7Once-Weekly Semaglutide in Adults with Overweight or ObesityN Engl J Med, 2021 · PMID 33567185
- 8Safety of pasteurised Akkermansia muciniphila as a novel food pursuant to Regulation (EU) 2015/2283EFSA J, 2021 · PMID 34484452
- 9Safety of an extension of use of pasteurised Akkermansia muciniphila as a novel food pursuant to Regulation (EU) 2015/2283EFSA J, 2025 · PMID 41018002
Akkermansia muciniphila and other dietary supplements are not intended to diagnose, treat, cure or prevent any disease, and these statements have not been evaluated by the FDA. Talk to your clinician or pharmacist before starting a supplement, especially if you take prescription medicines. This page has no product or affiliate links.